Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Research & Development: ¥521 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600267 Zhejiang Hisun Pharmaceutical Co Ltd SHSE:600267
58 GF Score
Price ¥11.72
GF Value ¥8.85
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Zhejiang Hisun Pharmaceutical Co Research & Development?

Zhejiang Hisun Pharmaceutical Co SHSE:600267 -1.18% 58 Research & Development is ¥521 Mil as of Mar. 2026. GuruFocus rates SHSE:600267 with a GF Score™ of 58/100 and a GF Value™ of ¥8.85 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Zhejiang Hisun Pharmaceutical Co's Research & Development for the three months ended in Mar. 2026 was ¥134 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥521 Mil.

Zhejiang Hisun Pharmaceutical Co  (SHSE:600267) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zhejiang Hisun Pharmaceutical Co Research & Development Related Terms

Zhejiang Hisun Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Zhejiang Hisun Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Hisun Pharmaceutical Co Research & Development Chart

Zhejiang Hisun Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 372.80 428.69 391.95 357.69 478.54

Zhejiang Hisun Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.43 109.94 169.79 106.39 134.44
SHSE:600267
58GF Score
Zhejiang Hisun Pharmaceutical Co Ltd SHSE:600267
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Hisun Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥521 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥521 Mil mean?
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) has a Research & Development of ¥521 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors.
Is Zhejiang Hisun Pharmaceutical Co's Research & Development too high?
Zhejiang Hisun Pharmaceutical Co's current Research & Development is ¥521 Mil. Overall, Zhejiang Hisun Pharmaceutical Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Hisun Pharmaceutical Co's Research & Development compare to ZTS?
Zhejiang Hisun Pharmaceutical Co's Research & Development of ¥521 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. Zhejiang Hisun Pharmaceutical Co's current Research & Development is ¥521 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Hisun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co (SHSE:600267) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.85, compared to a current price of ¥11.72 — trading 32.4% above its estimated fair value. The current Research & Development is ¥521 Mil. Zhejiang Hisun Pharmaceutical Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Zhejiang Hisun Pharmaceutical Co (SHSE:600267), the current Research & Development is ¥521 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥11.72 is trading 32.4% above its estimated GF Value™ of ¥8.85. GuruFocus considers Zhejiang Hisun Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:600267:

  • Research & Development: ¥521 Mil
  • GF Value™: ¥8.85 vs. price of ¥11.72 (32.4% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Hisun Pharmaceutical Co Business Description

Address No. 46 Waisha Road, Jiaojiang District, Zhejiang Province, Taizhou, CHN, 318000
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
58GF Score

Get the complete analysis for SHSE:600267

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.72
Price
¥8.85
GF Value